ReviewBreast cancer (Tokyo, Japan)2021
Fibromatosis of the breast: a 10-year multi-institutional experience and review of the literature.
Review in Breast cancer (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Desmoid-Type Fibromatosis of the Male Breast Associated with Bilateral Gynecomastia: Diagnostic Challenges and Surgical Management.Journal of clinical medicine · 2026Article
- Atypical ultrasonic manifestation of dermatofibrosarcoma protuberans in a female patient: a case report of hyperechoic type and reflection on diagnosis and treatment.BMC women's health · 2026Article
- Gardner syndrome initially misdiagnosed as bilateral breast malignancy: a case report and literature review.Frontiers in oncology · 2026Article
- The Carcinoma Mimic: A Case of Breast Fibromatosis.Cureus · 2025Article
- Clinicopathological analysis of three cases of breast desmoid-type fibromatosis.BMC women's health · 2025Article
- Fibromatosis of the accessory breast mimicking a malignant tumor: a rare case report and literature review.Frontiers in oncology · 2025Article
- Article
- Diagnosis and Management of Desmoid Fibromatosis of the Breast.World journal of oncology · 2024Review
- Desmoid fibromatosis in a male breast with gynecomastia: A case report.Radiology case reports · 2024Article
- Mesenchymal Tumors of the Breast: Fibroblastic/Myofibroblastic Lesions and Other Lesions.Current oncology (Toronto, Ont.) · 2023Review
- Pitfalls in breast pathology.Histopathology · 2023Review
- Spindle cell lesions of the breast: a diagnostic approach.Virchows Archiv : an international journal of pathology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast fibromatosis is a rare clinical entity, but poses significant diagnostic and therapeutic challenges. In light of recent changes in management practices, the aim was to review our institutional experience of breast fibromatosis and provide a review of current available literature on such management.
methodsA search of pathological databases within two tertiary institutions for all patients diagnosed with fibromatosis of the breast over a 10-year period (2007-2016) was performed. Clinicopathological characteristics and modes of treatment were recorded for each patient. Concurrently a comprehensive literature search was performed and studies relating to breast fibromatosis and its management were identified and reviewed.
resultsSixteen patients were identified. Median age at diagnosis was 42 (range 21-70) and all patients were diagnosed with core biopsy. The most useful imaging modality in diagnosis was ultrasonography and magnetic resonance imaging. 13/16 were treated surgically whilst 3/16 were treated using a watch-and-wait approach. 6/13 (46%) required re-excision of margins and 2/13 (15%) had recurrence after surgery. On review of the literature, there is no dedicated guideline in place for the management of breast fibromatosis. Currently a 'watch and wait' approach is favoured over surgical intervention due to high levels of recurrence and associated surgical morbidity. All cases should be discussed at a sarcoma multidisciplinary team meeting and tyrosine kinase inhibitors should be considered in advanced cases.
conclusionsBreast fibromatosis is rare but affects young patients. Active surveillance is now favoured over surgical resection due to high recurrence rates and extensive morbidity. Dedicated guidelines are required to ensure best outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.